Sorrento Therapeutics (SRNE) Targeting The Same Targets as LLY's Treatment Entering Human Testing
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $24.00 price target on Sorrento Therapeutics (NASDAQ: SRNE) after Eli ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
